<DOC>
	<DOCNO>NCT01363401</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy autologous bone marrow-derived stem cell ( `` HYNR-CS inj '' ) , intrathecal delivery treatment patient ALS . This study consist 2 step . First step safety study intrathecal ( IT ) injection `` HYNR-CS inj '' 8 patient ALS . In phase 1 study , AE , laboratory test , physical examination , vital sign , Electrocardiogram , Chest X-Ray examination evaluate term safety . Second step compare efficacy safety test group control group total 64 patient ALS .</brief_summary>
	<brief_title>Safety Efficacy Study Autologous Bone Marrow Derived Stem Cell Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis progressive neurodegenerative disease characterize motor neuron loss . Despite many trial disease-modifying , treatment far change natural course disease . We perform pre-clinical clinical study use autologous bone marrow-derived stem cell ALS . We could get evidence autologous bone marrow-derived stem cell dose-dependent effect SOD1 mouse via intrathecal injection . In result clinical trial , intrathecal injection autologous bone marrow-derived stem cell could slow disease progression might use disease modify strategy patient ALS . This study design single center , randomize , open-label , parallel-group , 2-stage study , target patient diagnosed Amyotrophic Lateral Sclerosis ( Lou Gehrig 's disease ) . The study consist Stage-1 study safety evaluation Stage-2 study efficacy safety evaluation study drug , Stage 1 , 7 subject eligible inclusion/exclusion criterion receive safety evaluation 28 day study drug administration twice protocol , follow Stage 2 . To decide whether study proceed 2 stage , ADR ( CTCAE Version 3.0 , ≥grade 3 ) appear initial 7 subject . Data obtain subject study analyze three : Safety Analysis , ITT ( Intent-To-Treat ) Analysis , PP ( Per Protocol ) Analysis . However , case phase 1 , safety analysis conduct , case phase 2 , safety , ITT , PP analyse conduct . For ITT Analysis , subject whose data primary efficacy endpoint could obtain follow administration investigational drug analyze analysis among subject administer investigational drug least . Also , Modified ITT Analysis , include 7 subject Stage 1 , carry .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Patients 25 75 year old Patients sign low motor neuron ( LMN ) upper motor neuron ( UMN ) degeneration clinical , electrophysiological neuropathologic examination Patients diagnose 'Probable ' 'Definite ' ALS accord World Federation Neurology El Escorial criterion Patients take Rilutek stable background dose 3 month ago least screening entry Patients whose duration disease within 5 year first diagnosis Patients ALSFRSR score within 31 46 screening Patients visit hospital walk personally protector 's help Patients provide write consent oneself his/her legal representative Patients n't appropriate diagnostic criterion ALS Patients diagnose primary lateral sclerosis ( PLS ) progressive muscular atrophy ( PMA ) Patients suspected adverse effect stem cell injection ( patient suspect malignant tumor , risk group psychogenic shock , patient serious hypertension ) Patients ALSFRSR score 30 screening Patients perform ventilator tracheostomy screening Patients perform gastrostomy screening Patients unable assess efficacy clinical trial due unattainable PFT ( Pulmonary Functional Test ) patient suspect 40 % less FVC screen Patients find myocardial infarction angina pectoris accord ECG , patient perform Stenting Bypass operation screen Patients take drug clinical trial within past 3 month screen entry Patients epilepsy Patients severe renal dysfunction ( serum creatinine≥2.0mg/dl ) Patients severe liver dysfunction ( ALT , AST , bilirubin≥upper limit normal X 2 ) Pregnant woman , lactate woman , female patient pregnancy plan n't agree adoption contraception method proper medically , male patient n't agree adoption contraception method proper partner participate study Patients hemorrhagic tendency screen Patients virus infection screen Patients know history hypersensitivity/allergy penicillin streptomycin Patients previous stem cell therapy Patients diagnose cancer Patients take drug thag effect bone marrow function Patients neurological disease except ALS Patients psychotic disease</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Motor neuron disease</keyword>
	<keyword>MND</keyword>
	<keyword>HYNR-CS inj</keyword>
	<keyword>Autologous bone marrow derive stem cell</keyword>
	<keyword>Intrathecal injection</keyword>
</DOC>